Fate Therapeutics (FATE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Fate Therapeutics (FATE) is Neutral.

The composite score behind that read is -0.10, weighing +0.06 of bullish evidence against -0.24 bearish.

Fate Therapeutics last closed at $2.18, +2.35% on the session.

Against the IVW growth benchmark the position is +1.55% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

10 graded predictions for FATE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Fate Therapeutics in the 15th percentile on return on equity, where 100 is best.

Fate Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $255.22M.

StockMap tracks Fate Therapeutics as the 225th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Fate Therapeutics ranks 221st of 381 in the group, against a group median of -0.08.